NRMT (N-terminal regulator of chromatin condensation 1 methyltransferase) was the first eukaryotic methyltransferase identified to specifically methylate the free α-amino group of proteins. Since the discovery of this N-terminal methyltransferase, many new substrates have been identified and the modification itself has been shown to regulate DNA-protein interactions. Sequence analysis predicts one close human homologue of NRMT, METTL11B (methyltransferase-like protein 11B, now renamed NRMT2). We show in the present paper for the first time that NRMT2 also has N-terminal methylation activity and recognizes the same N-terminal consensus sequences as NRMT (now NRMT1). Both enzymes have similar tissue expression and cellular localization patterns. However, enzyme assays and MS experiments indicate that they differ in their specific catalytic functions. Although NRMT1 is a distributive methyltransferase that can mono-, di-and tri-methylate its substrates, NRMT2 is primarily a monomethylase. Concurrent expression of NRMT1 and NRMT2 accelerates the production of trimethylation, and we propose that NRMT2 activates NRMT1 by priming its substrates for trimethylation.
INTRODUCTION
N-terminal methylation of free α-amino groups has been documented for many decades, but very little is known about the function of this modification [1] . Of the few eukaryotic proteins known to be N-terminally methylated, almost all contain an N-terminal Xaa-Pro-Lys consensus sequence (Rubisco being an exception [2] ), indicating that one specific enzyme might be responsible for this post-translational modification [1] . The first functional role of N-terminal methylation was determined by mutating the Ser-Pro-Lys consensus of the Ran guanine-nucleotide-exchange factor RCC1 (regulator of chromatin condensation 1) [3] . This resulted in loss of RCC1 N-terminal methylation, decreased affinity of RCC1 for DNA, mislocalization of RCC1 during mitosis and the formation of multi-polar spindles [3] . It has also recently been shown that the N-terminal glycine residues of CENP-A (centromere protein A) and CENP-B are N-terminally methylated [4, 5] . N-terminal methylation of CENP-B regulates its binding to centromeric DNA [5] and N-terminal methylation of CENP-A is predicted to help regulate the phasing of CENP-A nucleosomes on centromeric α-satellite DNA [4] . In addition to the regulation of protein-DNA binding, many N-terminally methylated proteins are found in large multisubunit complexes with their N-termini at locations of contact with neighbouring proteins, signifying this modification may also play a role in the regulation of protein-protein interactions [1] . N-terminal methylation is also protective against digestion by cellular aminopeptidases [6] and may interfere with N-terminal acetylation and the N-end rule pathway [7, 8] , indicating a role in protein stability.
The first eukaryotic N-terminal methyltransferase, NRMT (N-terminal RCC1 methyltransferase)/NTMT (now NRMT1; GeneID: 28989), was identified as the enzyme that methylates the N-termini of RCC1 [9] and the ribosomal proteins Rpl12 and Rps25 [10] . Accordingly, NRMT1 loss in human embryonic kidney cells results in decreased RCC1 localization to chromatin and increased multi-polar spindle formation during mitosis [9] . Yeast lacking NRMT1 have altered ribosomal profiles and defects in translational fidelity and efficiency [11] . We have previously shown that NRMT1 mono-, di-and tri-methylates an N-terminal Xaa-Pro-Lys (XPK) consensus sequence, with Xaa being any amino acid other than Leu, Ile, Trp, Asp or Glu [9] . Using this consensus sequence, we have also confirmed a variety of new NRMT1 substrates, including the tumour suppressor RB (retinoblastoma protein), the oncoprotein SET, the transcription factor Kelch-like protein 31, and numerous myosin light chains and ribosomal proteins [9] . Although NRMT1 substrates are numerous and predominantly abundant proteins, NRMT1 itself is ubiquitously expressed at considerably low levels (see Figure 5C ), suggesting that there may be an additional enzyme(s) capable of N-terminal methylation.
NRMT1 [formerly METTL11A (methyltransferase-like protein 11A)] is a member of the class I methyltransferase family, as it lacks a SET domain (common of the histone methyltransferases) and is composed of a seven β-strand structure. Sequence analysis indicates one close human homologue, methyltransferase-like Abbreviations used: AdoMet, S-adenosylmethionine; CENP, centromere protein; ETD, electron-transfer dissociation; EZH2, enhancer of zeste homologue 2; HEK, human embryonic kidney; me1/2-RCC1, mono-/di-methylated SPK-RCC1; me2-PPK, dimethylated PPK-RCC1; me3-RCC1, trimethylated SPK-RCC1; METTL, methyltransferase-like protein; MS/MS, tandem MS; NRMT, N-terminal regulator of chromatin condensation 1 methyltransferase; NSD, nuclear-receptor-binding SET domain protein; PRMT, protein arginine methyltransferase; RCC1, regulator of chromatin condensation 1.
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protein 11B (now renamed NRMT2; GeneID: 149281) [10] . Characterization of other methyltransferase families has shown that such close homologues usually differ in either their expression/localization patterns or their catalytic activity. For example, PRMT1 (protein arginine methyltransferase 1) and PRMT8 are both type I arginine methyltransferases from the PRMT family. They both methylate glycine/arginine-rich motifs, however, PRMT1 is ubiquitously expressed and PRMT8 is specifically expressed in the brain [12] . PRMT8 is also myristoylated, resulting in membrane-specific localization [12] . In comparison, the nuclear receptor-binding SET domain proteins NSD1 (nuclear-receptor-binding SET domain protein 1) and NSD2 are both nuclear histone methyltransferases. However, NSD1 is a histone H3 Lys 36 dimethylase [13] , whereas NSD2 is a histone H3 Lys 36 trimethylase [14] . In the present paper we report that NRMT2 is a functional Nterminal methyltransferase that also recognizes and methylates an XPK consensus sequence. NRMT1 and NRMT2, analogous to the NSD family of methyltransferases, have similar localization and expression patterns, but differ in their catalytic activity. NRMT1 is a distributive methyltransferase that can mono-, diand tri-methylate its substrates, whereas NRMT2 is primarily a monomethylase. We propose a model whereby their similar localization patterns allow NRMT2 to prime for NRMT1, allowing for quicker and more robust di-and tri-methylation of substrates. This regulatory mechanism would be especially useful in tissues with a high abundance of substrates.
MATERIALS AND METHODS

Constructs and antibodies
The SPK (serine-proline-lysine)-and APK (alanine-prolinelysine)-RCC1 substrates for determining NRMT2 consensus specificity were expressed from a modified pet15b vector (Novagen) and were processed by Factor X cleavage and purified as described previously [9] . The PPK (proline-proline-lysine)-RCC1 substrate was expressed in pet30a as described previously [3] . Human NRMT1 and mouse NRMT2 (Open Biosystems) were cloned into the XbaI and BamHI sites of pKGFP2 to remove one copy of GFP and create the NRMT1-GFP and NRMT2-GFP constructs for cellular localization experiments. Human NRMT1 and human NRMT2 (Open Biosystems) were cloned into the NdeI and XhoI sites of pet15b for production of recombinant protein. The recombinant human RCC1 substrate was expressed in pET30a [3] . All His-tagged proteins were purified as described previously [15] .
Primary antibodies used for Western blot analysis are as follows: 1:20000 dilution rabbit anti-me3-RCC1 (trimethylated SPK-RCC1) [3] , 1:10000 dilution rabbit anti-me1/2-RCC1 (mono-/di-methylated SPK-RCC1) [3] , 1:1000 dilution rabbit anti-me2-PPK (dimethylated PPK-RCC1), 1:1000 dilution goat anti-RCC1 (Santa Cruz Biotechnology, sc-1162), 1:1000 dilution rabbit anti-NRMT1 [9] and 1:3000 dilution mouse anti-β-catenin (BD Biosciences).
NRMT2 rescue assay
Lentivirus was produced through calcium-phosphate transfection of 2.5×10 6 HEK (human embryonic kidney)-293LT cells with the viral envelope plasmid pMD2.G, the viral packaging vector psPAX2 and pGIPZ (Open Biosystems) containing the shRNAmir and/or the rescuing cDNA. A total of 10000 HEK-293LT cells were infected with lentivirus (control, NRMT1 shRNAmir, NRMT1 shRNAmir co-expressing murine NRMT1-FLAG or NRMT1 shRNAmir co-expressing murine NRMT2-FLAG) to an MOI (multiplicity of infection) of 3. The cells were grown for 2 days and transduced cells were selected by addition of 2 μg/ml puromycin. The cells were grown for an additional 2 days and lysed in lysis buffer (500 mM NaCl, 50 mM Tris/HCl, pH 8.0, 5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 0.1% Nonidet P40, 2-mercaptoethanol and protease inhibitors). Each lysate (50 μg) was analysed by Western blotting.
In vitro methylation assays
In vitro methylation reactions with Factor-X-digested substrates were done as described previously [9] . For the assays determining catalytic specificity (both by Western blot and MS), 1 μg of recombinant human enzyme was mixed with 1 μg of recombinant RCC1 substrate in the presence of 100 μM AdoMet (Sadenosylmethionine) (Sigma-Aldrich). The reaction volume was brought to 20 μl with methyltransferase buffer (50 mM Tris/HCl, pH 8, and 50 mM potassium acetate). Each reaction was run for 60 min at 30
• C to ensure that the reaction ran to completion. For mechanistic studies, 25-500 ng of recombinant enzyme was mixed with 1-2 μg recombinant RCC1 substrate in the presence of 100 μM AdoMet. The reaction volume was adjusted to 20 μl with methyltransferase buffer and run for 2.5-30 min at 30
• C depending on the experiment. An aliquot (5 μl) of the total reaction was analysed in each lane of the Western blots. Measurements of mono-, di-and tri-methylation of RCC1 were done on the same reactions. Western blot images were taken with the ChemiDoc MP Imaging System (Bio-Rad Laboratories) and percentage RCC1 trimethylation was quantified using Image Lab (Bio-Rad Laboratories) software. Briefly, identical boxes were used to measure the intensity of each trimethylated band and the corresponding total RCC1 loading control. The methylated intensity was divided by the total RCC1 intensity and multiplied by 100 to give percentage RCC1 trimethylation.
MS analysis
The analysis for the presence and extent of RCC1 N-terminal methylation was conducted as described by Chen et al. [3] with some modifications. In vitro methylated RCC1 proteins were resolved on SDS/PAGE gels and bands were visualized using Coomassie Blue stain. The gel bands were excised, destained and equilibrated into 0.1 M triethylammonium bicarbonate, pH 8.5, and digested with 100 ng Asp-N (Roche) per gel plug. The digest supernatant was transferred to a new tube and the gel plugs extracted using a modification of the methods described by Shevchenko et al. [16] . The digest and extract were combined, dried by SpeedVac (Savant, Thermo Scientific) and resuspended in 20 μl of 0.1% formic acid/2 % acetonitrile and then filtered through 0.2 μm regenerated cellulosic syringe filters (National Scientific, Thermo Scientific). A 5 μl aliquot of this peptide solution was loaded on to a Dionex Acclaim PepMap 100 75 μm×2 cm, nanoViper [C 18 , 3 μm, 100 Å (1 Å = 0.1 nm)] trap, and resolved on a Dionex Acclaim PepMap RSLC 50 μm×15 cm, nanoViper (C 18 , 2 μm, 100 Å) separating column. The sample was eluted using a linear 2-60 % acetonitrile gradient using an EASY nano1000 UHPLC and introduced into a LTQ-Orbitrap ELITE mass spectrometer (ThermoElectron) for accurate mass measurements using a Nanospray Flex Ion Source (ThermoElectron), a stainless steel emitter with a capillary temperature set to 225
• C and a spray voltage of 1.6 kV and lock mass enabled (0 % lock mass abundance) for the 371.101236 m/z polysiloxane peak as an internal calibrant [17] . Tandem mass spectra were collected using HCD (higher-energy C-trap dissociation) and ETD (electron-transfer dissociation) fragmentation using an Nth Order Double Play with ETD Decision Tree method [18] created in Xcalibur v2.2. Targeted and data-dependent spectra were acquired and searched using MASCOT version 2.1 through Proteome Discoverer 1.4 considering up to two missed cleavages, as well as phosphorylation and N-terminal methylation as variable modifications. All spectra MS/MS (tandem MS) for RCC1 were manually interpreted. Extracted ion chromatograms for the + 2, + 3 and + 4 charge states for individual N-terminal RCC1 peptides were aggregated and used to estimate relative abundances of modified and unmodified, normal and des-Met (lacking the initiating methionine residue) truncated N-terminal RCC1 peptides.
NRMT1 and NRMT2 localization
For live-cell imaging, HeLa cells were plated in two-well Lab-Tek II coverglass (Nunc) in DMEM (Dulbecco's modified Eagle's medium)/F12 50/50 without Phenol Red (Cellgro) supplemented with 10 % (v/v) FBS (Gibco) and transiently transfected with 2.0 μg of NRMT1-GFP, NRMT2-GFP or pKGFP-GFP using Lipofectamine TM 2000 (Invitrogen). After 24 h, cells were counterstained with DRAQ5 dye (1 μg/ml), imaging was performed on a Zeiss LSM510 Meta confocal microscope, using a 100× oil immersion lens [NA (numerical aperture) 1.3], at 512×512 pixel resolution, and a zoom of 2.0. Images were processed and quantified using ImageJ 1.41b software (NIH).
Quantification of mRNA in mouse tissue
Mouse tissue was obtained in-house after the animals were killed. Mice were killed by inhalation of carbon dioxide in a clear container followed by cervical dislocation. This method is consistent with the 2000 Report of the AVMA Panel on Euthanasia. No experimental procedures were performed while the mice were alive. The work was undertaken as required by national and institutional (University of Louisville) IACUC committees (approved IACUC proposal #11072). RNA isolation was performed by homogenization of tissues in TRIzol ® (Life Technologies) using the Powermax TM Advanced Homogenizing System 200 (VWR). Samples were then mixed with chloroform to extract RNA, the RNA was pelleted using propan-2-ol, and then washed with ethanol. cDNA was synthesized using the SuperScript First-Strand Synthesis System (Invitrogen). qPCR (quantitative real-time PCR) was performed with SYBR Green PCR Master Mix and the CFX96 Touch TM Real-Time PCR Detection System and Sequence Detection Software (Bio-Rad Laboratories). Primers (Integrated DNA Technologies) were designed using Primer 3 v 0.4.0. Primers sequences were 5 -TCTTCCCCCAGGTAGCTCT-3 and 5 -TGCAGAGGTTTTTAAGGGAAG-3 for NRMT1; and 5 -CT-TTCAGAGCTACCTCTACC-3 and 5 -GAAATTCACGAGAG-GCTTGG-3 for NRMT2. Gene expression was analysed using a standard curve as described previously [19] , as there were no housekeeping controls expressed at comparably low levels and constant between tissues. All qPCR assays included analysis of melting curves and agarose gel electrophoresis to confirm the presence of single PCR reaction products. The identity of NRMT1 and NRMT2 qPCR products was confirmed by sequencing (DNA Sequencing Core, University of Louisville, Louisville, KY, U.S.A.).
RESULTS
Substrate specificity of NRMT2 is similar to NRMT1
NRMT1 has one close human homologue, METTL11B [10] , which we renamed NRMT2. The amino acid sequence identity between NRMT1 and NRMT2 is close to 50 %, with all the catalytic residues being fully conserved (Figure 1 ). NRMT2 has an additional 60-amino-acid N-terminal domain, which models as two α-helices (Figure 2A) . Homology modelling by the Robetta server [20] showed that the overall fold of the catalytic domain of NRMT2 is highly similar to NRMT1 (RMSD less than 2.0 Å), with all the critical catalytic residues occupying the same spatial positions ( Figure 2B) Figure 2B ). The modelling also reveals conserved aromatic residues in the active sites of NRMT1 and NRMT2 ( Figure 2C ) that are reminiscent of the aromatic residues of chromodomains and may be responsible for binding methylated substrates or products [7] .
Sequence and structural similarity of NRMT1 to NRMT2 suggest that these two enzymes probably have similar enzymatic activities and substrate specificities. To test whether NRMT2 is capable of methylating SPK, PPK or APK N-terminal consensus sequences (which can all be recognized by our antime2-PPK RCC1 antibody), we employed a system in which Factor X cleavage provides efficient exposure of the residue to be methylated [9] . In vitro methylation assays showed that recombinant NRMT2 is capable of methylating SPK, PPK and APK recombinant substrates ( Figure 3A) . Furthermore, Cterminally FLAG-tagged murine NRMT2 expressed in HEK-293LT cells is capable of rescuing NRMT1 knockdown and restoring efficient RCC1 αN-methylation, indicating that the enzymes have overlapping catalytic activities ( Figure 3B ). However, we had previously seen that rescuing NRMT1 knockdown with NRMT1-FLAG restores both RCC1 mono-/diand tri-methylation [9] , but rescue with NRMT2-FLAG only restores RCC1 mono-/di-methylation ( Figures 3B and 3C ).
Catalytic activity of NRMT2 differs from NRMT1
To verify the rescue experiments indicating that NRMT2 does not have trimethylase activity, we performed in vitro methylation assays with recombinant human NRMT1 or recombinant human NRMT2 as the enzyme and recombinant human RCC1 as the substrate. The reaction was performed for 60 min at 30
• C in the presence of 100 μM AdoMet with 1 μg each of enzyme and substrate. These conditions were chosen to ensure the reaction went to completion and the amount of enzyme was not rate limiting. The reaction was then run on SDS/PAGE and analysed by Western blotting with anti-me1/2-RCC1 and anti-me3-RCC1 antibodies. After 60 min, little RCC1 mono-/di-methylation is seen following incubation with NRMT1, but higher levels are seen with NRMT2 ( Figure 4A ). In contrast, when looking at RCC1 trimethylation, there are high levels following incubation with NRMT1, but none after NRMT2 treatment ( Figure 4A ). These data indicate that, after 60 min, NRMT1 is capable of almost completely trimethylating RCC1, whereas NRMT2 can only complete dimethylation.
As the anti-me1/2-RCC1 antibody recognizes both mono-and di-methylation, we wanted to use MS to verify that NRMT2 was capable of both N-terminal mono-and di-methylation. The same in vitro methylation reactions were performed as Multiple sequence alignment of truncated NRMT2 (NRMT2d, which lacks the 60 amino acid N-terminal domain; UnitProt entry Q5VVY) and NRMT1 (UniProt entry Q9BV86) shows sequence identity as high as 50 % and sequence similarity at 75 %. Identical and similar amino acids are in shaded grey boxes.
above, run on SDS/PAGE, and stained with Coomassie Brilliant Blue. The RCC1 protein band was excised and analysed for N-terminal methylation by MS. As observed by Western blot, LC-MS/MS analysis indicated that the NRMT1 reaction produced almost complete trimethylation of RCC1 ( Figure 4B and Supplementary Figure S1 at http://www.biochemj.org/bj/456/ bj4560453add.htm). However, surprisingly, the NRMT2 reaction only produced significant levels of monomethylation ( Figure 4C and Supplementary Figure S1 ), indicating that NRMT2 is primarily an N-terminal monomethylase.
NRMT2 localization and tissue expression
Now knowing that NRMT1 and NRMT2 have different catalytic activities, we were interested in determining whether they also have different cellular localization patterns. We tagged NRMT2 with GFP and expressed it in HeLa cells. Similarly to NRMT1 [9] ( Figure 5A ), immunofluorescence analysis shows that NRMT2 is enriched in the nuclear compartment as compared with a GFP-GFP control protein ( Figure 5A ). The nuclear to cytoplasmic ratio of NRMT1 and NRMT2 was also quantified and found to be significantly different from that of the GFP-GFP control ( Figure 5B ).
As we determined that NRMT1 and NRMT2 have similar cellular localization patterns, we next analysed their tissue distribution. qPCR analysis was performed for both NRMT1 and NRMT2 in mouse tissue lysates. Both enzymes are expressed at fairly low levels in all tissues examined (approximately 100-200 copies of transcript per 40 μg of cDNA). However, NRMT1 mRNA is enriched in the brain, NRMT2 mRNA is enriched in the liver, and both are enriched in skeletal muscle ( Figures 5C  and 5D ). Owing to the low expression levels, we confirmed the specificity of the NRMT1 and NRMT2 qPCR reactions by sequencing the products to verify that the correct targets were amplified (results not shown).
NRMT2 primes for NRMT1
To establish a functional distinction between two N-terminal methyltransferase family members that have such similar subcellular localization and tissue expression profiles, we performed enzyme assays with NRMT1 and NRMT2 individually or in combination. We hypothesized that one reason for overlapping localization and expression patterns is that NRMT1 and NRMT2 are working synergistically. Lysine residue methylation has been shown to occur by one of two mechanisms, processive or distributive [21] . Processive methyltransferases can add up to three methyl groups without dissociation from the substrate. Therefore trimethylation by these enzymes is not dependent on the concentration of a previously mono-or dimethylated substrate. In contrast, distributive methyltransferases add a methyl group, then must dissociate from the substrate before additional methyl groups can be added [21] . Increasing the amount of previously mono-or di-methylated substrate can thereby increase di-or tri-methylation by these methyltransferases.
The complex pattern of RCC1 N-terminal methylation in mammalian cells (5 % unmethylated, 20 % monomethylated, 30 % dimethylated and 45 % trimethylated) [3] indicates that NRMT1 is distributive or has an extremely low k cat . If NRMT1 is distributive, NRMT2 should be able to increase NRMT1 di-and tri-methylation activity by increasing the pool of monomethylated substrates available. This would be especially useful in the presence of high concentrations of substrate.
We analysed the methylation mechanisms of NRMT1 and NRMT2 by performing in vitro methylation assays with increasing concentrations of recombinant enzyme and a constant concentration of substrate (recombinant human RCC1). If the reaction time is kept constant, a processive enzyme will produce different amounts of only one methylation state. However, a distributive enzyme will produce all three methylation sites, with the highest order of methylation occurring slowly and dependent on the concentration of enzyme [21] . As shown in Figure 6 (A), at low concentrations of NRMT1 we first observe robust RCC1 mono-/di-methylation. Increasing the concentration of NRMT1 results in a gradual accumulation of RCC1 trimethylation with a corresponding decrease in RCC1 mono-/ di-methylation ( Figure 6A ). The appearance of both mono-/ di-and tri-methylation, the order in which they appear, and the eventual decrease in RCC1 mono-/di-methylation, indicate that NRMT1 is a distributive trimethylase.
In contrast, when using NRMT2 as the enzyme, we only observe RCC1 mono-/di-methylation, which we now know from the MS data is predominantly monomethylation (Figure 6B ). These levels rise with increasing concentration of NRMT2 and do not decrease at high levels of enzyme, as seen with NRMT1. We do not see the appearance of RCC1 trimethylation ( Figure 6B ), further confirming that NRMT2 is not a trimethylase. When NRMT1 and NRMT2 are combined in a reaction, RCC1 trimethylation appears more rapidly and intensely ( Figures 6C and 6D ), indicating that NRMT2 can serve as an activator/primer for NRMT1 trimethylation.
DISCUSSION
The experiments of the present study verify for the first time that NRMT2 is an N-terminal methyltransferase, that it has a different catalytic specificity from its homologue NRMT1, and that it can prime NRMT1 substrates for higher degrees of methylation. NRMT1 and NRMT2 are not the first highly similar methyltransferase family members to differ in their specific catalytic functions. The nuclear receptor SET domain-containing methyltransferases NSD1, NSD2 and NSD3 are almost identical in a 700-amino-acid stretch (including their catalytic domain), yet bind histone H3 differently and catalyse different levels of methylation at Lys 36 [13, 14, 22] . Structural studies indicate the differences in the NSD methyltransferases comes from their chromatin-binding motifs, which target them to different promoter regions [22] . Comparison of NRMT1 crystal structure and NRMT2 homology model indicate that the main region of variance between the two homologues is the additional N-terminal domain of NRMT2. These additional bulky helices could easily prevent binding of NRMT2 to previously methylated substrates. Thus it will be interesting to see whether deleting the N-terminal domain of NRMT2 will allow it to di-and tri-methylate its substrates. It would also be interesting to determine whether switching the conserved trio of aromatic residues in the active sites of NRMT1 and NRMT2 could switch their catalytic activities. Although similar in structure (Figure 2C ), the exact residues differ slightly and could dictate binding of unmethylated compared with mono-or di-methylated substrates (see below) [23] .
The inability of NRMT2 to di-or tri-methylate XPK substrates in vitro indicates that it is primarily a monomethylase. However, NRMT1 is capable of trimethylation in vitro, demonstrating that the two enzymes do have inherent catalytic differences and may be differentially regulated. For example, the monomethylase activity of NRMT2 may protect it from product feedback inhibition. We have previously shown that NRMT1 can bind to and become inhibited by its di-and tri-methylated products [7] . As NRMT2 is not able to di-and tri-methylate substrates, it is also unlikely to bind these products. Di-and tri-methylated species constitute the majority of N-terminally methylated proteins in the cell [3] , so NRMT2 expression could be used to alleviate or bypass this inhibition. This would be especially useful in tissues such as skeletal muscle, which contains high amounts of trimethylated myosin proteins [9] . Higher NRMT2 expression in skeletal muscle ( Figure 5D ) may aid NRMT1 strained by substrate burden and product inhibition. It is currently unclear why NRMT1 mRNA is enriched in the brain and NRMT2 mRNA is enriched in the liver. However, these unique aspects of their expression patterns suggest they are serving non-redundant tissue-specific functions. In addition, loss of NRMT1 activity alone has phenotypic consequences both in vitro [9] and in vivo (C.E. Schaner Tooley, unpublished work), indicating that NRMT1 and NRMT2 have non-redundant roles during cell growth and development. These data also demonstrate that N-terminal monomethylation and di-/tri-methylation serve non-redundant functions. There is mounting evidence of distinct functional roles for different levels of histone methylation, with the extent of methylation often controlling the binding of effector proteins [24] . There is also evidence that disruption of these levels has extreme biological effects. The histone methyltransferase EZH2 (enhancer of zeste homologue 2) is predominantly a histone H3 Lys 27 (H3K27) monomethylase [23] . However, in a subset of follicular lymphoma and diffuse-large B-cell lymphomas there is a gain-of-function tyrosine to phenylalanine mutation at amino acid 641 (Y641F) in the active site that turns EZH2 into a H3K27 trimethylase [23] . It is proposed that this change in methylation ability alters the transcription levels of different tumour suppressors regulated by EZH2, leading to the progression of B-cell tumorigenesis [23] .
In the same way, mutations that alter the expression levels or catalytic functions of NRMT1 or NRMT2 could produce developmental defects and lead to disease. In fact, mutations in both NRMT1 and NRMT2 have been found in a variety of cancers, including point mutations in the NRMT2 active site [25] [26] [27] (Cosmic Catalogue of Somatic Mutations in Cancer; http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). NRMT1 is overexpressed in colon and rectal cancers [28, 29] , indicating an increase in di-/tri-methylated substrates may exacerbate the pathology of these diseases. However, in breast cancer, NRMT1 expression is more often decreased [30] [31] [32] , indicating di-/tri-methylated substrates may be protective against this pathology or an increase in monomethylated substrates may be particularly detrimental. It will be interesting to now analyse NRMT2 levels in these disease states and see how they correspond, and to determine whether NRMT1 and NRMT2 mutations are commonly found in the same tumour samples. It will also be interesting to identify exactly which N-terminally methylated targets play a role in each disease state and to determine whether the particular targets differ between cancer types.
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